Roles
- Associate Professor of Clinical Neurology
-
Biography
Dr. Henry Moore joined the Department as an Assistant Professor of Clinical Neurology. He earned his undergraduate and medical degree at Universidad Peruana Cayetano Heredia – School of Medicine, Lima – Peru. He performed his Neurology Residency at Jackson Memorial Hospital / University of Miami – Miller School of Medicine. Then, he performed a 2-year Movement Disorders Fellowship at Jackson Memorial Hospital / University of Miami – Miller School of Medicine. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
How Art and Deep Brain Stimulation Help One Man Live Fully With Parkinson’s Disease
Preserving Brain Health and Advancing Neuroscience
New Center Expands Services to Parkinson’s Disease Community, Targeting Underserved Spanish-Speaking Population
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 11 clinical trials.
-
This study evaluates the effects of Sage 718 treatment on mild cognitive impairment (involving mental activities like thinking, learning, decision-making, and remembering) and dementia.Mild cognitive impairment is a condition that is associated with decreased quality of life and impaired functioning and is common in people who have Parkinson’s Disease (PD).
- Principal Investigator: Henry Moore
- Study Phase: TBD
- Enrollment Status: Closed
-
The purpose of the study is to demonstrate the effectiveness of AP-472 as an adjunctive therapy to Levodopa in improving motor disability associated with motor fluctuations and attenuating the severity of dyskinesia, and asses benefits and risks of this drug. AP-472 may represent a unique treatment for PD, given its potential to reduce motor fluctuations and minimize dyskinesia simultaneously.
- Principal Investigator: Henry Moore
- Study Phase: TBD
- Enrollment Status: Open
-
The purpose of the trial is to compare the safety and effects of Votoplam to a placebo in people with Huntingtons disease (HD) and to determine if Votoplam can help slow down the worsening of HD symptoms through HD‑specific rating scales and check for changes in the brain and in the body. Also, include looking at certain tests, called biomarkers, that show how the disease and the treatment are affecting HD patients.
- Principal Investigator: Henry Moore
- Study Phase: TBD
- Enrollment Status: Open
-
This is a long-term (365 days) Phase 3,open-label, multicenter safety study to evaluate the safety and tolerability of SAGE-718 in treating cognitive disorders in premanifest or early manifest HD subjects. The estimated total sample will be 300 subjects.The study has been extended up to 4 years.
- Principal Investigator: Henry Moore
- Study Phase: TBD
- Enrollment Status: Closed
-
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
- Principal Investigator: Henry Moore
- Study Phase: Phase 3
- Enrollment Status: Closed
-
Opicapone Treatment Initiation Open-Label Study
- Principal Investigator: Henry Moore
- Study Phase: Phase IV
- Enrollment Status: Closed
-
UCB has been leading research in early Parkinsons disease (PD). The protocol is designed to collect further qualitative evidence: (i) to identify the items within the MDS-UPDRS parts II and III that could be relevant and clinically meaningful in early PD; and (ii) for refining the two novels patient-reported outcome (PRO) instruments. The background and specific research objectives of each research stream :The overall objective of the first research stream is to identify the ‘events, ‘signs or ‘symptoms; and subsequently MDS-UPDRS items most relevant to characterize early PD and disease progression. Specifically, the first research stream will aim to:• Identify the items of MDS-UPDRS parts II and III that may be the most relevant in early PD patients, and compare them with the items shortlisted by UCB through quantitative analyses;• Identify the items of MDS-UPDRS parts II and III that may best capture clinically meaningful change and disease progression; and compare them with the items shortlisted by UCB through quantitative analyses;• In the context of interviews with people with early PD, what symptom(s), sign(s), or event(s) prompted them to consult a neurologist to seek treatment for the first time;• In the context of interviews with clinicians specifically, what may be the ‘events within early PD that define disease progression.For this objective, we will conduct semi-structured interviews with people with early PD, their relatives, and movement disorder specialist (MDS) neurologists.The overall objective of the second research stream will be to collect qualitative feedback on the two novel PRO instruments item relevance, clarity; and ease of selecting a response option. The qualitative feedback will be used to inform item reduction, identify any missing concepts, and the most clinically meaningful items, which are in the best position to reflect disease progression.For this purpose, semi-structured cognitive debriefing interviews will be conducted with people with early PD.The Study Design is a qualitative study comprising interviews across the United States (US) and the Netherlands (NL) will be conducted with n=50 people with clinically established PD (n=30 in the US and n=20 in the NL) comprising the main research participants, supplemented by a small interview consultation with n=10 relatives of people with PD and n=10 MDS neurologists. All 70 participants will take part in stream 1 of the research study, whilst the people with clinically established PD (n=50) will be followed up for a second interview in the second stream of the study.The Inclusion Criteria:• Idiopathic PD, classified by the MDS diagnostic criteria [8], confirmed by a neurologist• 5 years or less since diagnosis• Aged between 40 and 85 inclusive• Consent to participate in the study including the audio-recording of the interviews
- Principal Investigator: Henry Moore
- Study Phase: TBD
- Enrollment Status: Closed
-
This is a randomized, placebo-controlled, double-blind, parallel group study with a 28-day treatment duration to evaluate the effects of SAGE-718 on functioning capacity, safety, and tolerability inparticipants with early manifest HD. Participants will be adults with genetically-confirmed expansion of the Huntingtin (HTT) gene cytosine, adenine, and guanine (CAG) trinucleotide repeat at Screening.
- Principal Investigator: Henry Moore
- Study Phase: Phase II
- Enrollment Status: Closed
-
This is a Phase 4,15-month (9-month enrollment and 6-month follow-up), prospective, noninterventional, single-arm, single-country (US), multicenter, 2-cohort (TD and HD) study to assess real-world utilization of deutetrabenazine that is initiated by a 4-week patient titration kit for the treatment of TD or chorea associated with HD.Patients should have been prescribed deutetrabenazine and provided with the 4-week patient titration kit before consenting to and enrolling in the study. Visit 1 (week 0, day 0) is the enrollment and baseline visit. Day 1 is the first day that the patient takes deutetrabenazine from the 4-week patient titration kit. The next visit may occur around week 4 of titration (ie, just before the patient titration kit is completed). The suggested visit interval for all visits is approximately every 4 weeks (7 days) for a total of 7 visits (24 weeks total) per routine patient care at the discretion of their HCP.
- Principal Investigator: Henry Moore
- Study Phase: Phase IV
- Enrollment Status: Closed
-
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease
- Principal Investigator: Henry Moore
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The current study will explore the efficacy, safety, andtolerability of the individual components of JM-010 (buspironeand zolmitriptan), as well as 2 dose combinations of JM-010 todetermine the optimal doses of each component to be studied inconfirmatory clinical trials.Objectives: Part 1: Dose-Finding Phase of Individual Components ofJM-010Primary Objective:To determine the safety and tolerability of buspirone(administered at 2 different doses) and zolmitriptan in PDpatients.Secondary Objective:To compare the efficacy of buspirone (administered at 2 doselevels) and zolmitriptan therapy to that of placebo therapy inreducing dyskinesia severity in PD.Part 2: Efficacy and Safety Assessment with JM-010Combination ProductPrimary Objective:To compare the efficacy of JM-010 (administered as 2 distinctdose combinations of buspirone and zolmitriptan) and buspironetherapy to that of placebo therapy in reducing dyskinesiaseverity in PD.Secondary Objectives:Efficacy:To compare the efficacy of JM-010 (administered as 2 distinctdose combinations of buspirone and zolmitriptan) and buspironetherapy to that of placebo therapy in parkinsoniandisability/disease progression and change in PD symptoms.Safety and Tolerability:To determine the safety and tolerability of JM-010 (administeredas 2 distinct dose combinations of buspirone and zolmitriptan)and buspirone in PD patients.
- Principal Investigator: Henry Moore
- Study Phase: Phase II
- Enrollment Status: Closed